Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07402213 Ozureprubart Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07402213 clinical trial report covering Ozureprubart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260526 Nifuratel/Nystatin Vaginitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260526 clinical trial report covering Nifuratel/Nystatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260472 Beclometasone Dipropionate/Formoterol Fumarate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260472 clinical trial report covering Beclometasone Dipropionate/Formoterol Fumarate, Phase 3, endpoints, sponsor, geography, readout timing and devel
Latest Hotspot
8 min read
NCT07407517 Everolimus Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07407517 clinical trial report covering Everolimus, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600118933 Toripalimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600118933 clinical trial report covering Toripalimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07404865 Telitacicept Primary Sjögren's syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07404865 clinical trial report covering Telitacicept, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07406542 SYS-6010 HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07406542 clinical trial report covering SYS-6010, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07405164 Nivolumab Von Hippel-Lindau Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07405164 clinical trial report covering Nivolumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07407803 TQ-B3234 Plexiform Neurofibroma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07407803 clinical trial report covering TQ-B3234, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07407140 Venetoclax Acute Myeloid Leukemia with FLT3/ITD Mutation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07407140 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07405970 Obinutuzumab β Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07405970 clinical trial report covering Obinutuzumab β, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07406360 Measles, Mumps and Rubella Vaccine (GSK) Rubella Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07406360 clinical trial report covering Measles, Mumps and Rubella Vaccine (GSK), Phase 3, endpoints, sponsor, geography, readout timing and development